<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="200410">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00481273</url>
  </required_header>
  <id_info>
    <org_study_id>AVIDA</org_study_id>
    <nct_id>NCT00481273</nct_id>
  </id_info>
  <brief_title>AVIDA The Vidaza® (Azacitidine) Patient Registry</brief_title>
  <acronym>AVIDA</acronym>
  <official_title>AVIDA The Vidaza® (Azacitidine) Patient Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry is a prospective, multi-center, observational study compiling data on the
      natural history and management of patients receiving Vidaza, and will provide unique
      insights into the management of myelodysplastic syndromes (MDS) and other hematological
      disorders and the impact of these disorders on patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vidaza usage</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Describe current usage patterns for Vidaza in the community</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concomitant care and treatment</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Document common concomitant care procedures and treatments used in conjnction wtih Vidaza</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration and number of cycles</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Correlate duration and number of Vidaza treatment cycles with clinical response as defined by 2006 International Working Group for Myeleodysplastic Syndrome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Publication</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Produce publications to support further clinical development and disseminate information on treatment best practices</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">479</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Physician's discretion</description>
    <other_name>Vidaza(R)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Community-based hematology/oncology centers
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who is deemed appropriate for treatment with Vidaza® by his or her clinician,
             but who has not already started receiving Vidaza® treatment.

          -  Patient who is able to read and speak English.

          -  Patient who is willing and able to provide informed consent.

          -  Patient who agrees to complete patient assessment questionnaires.

        Exclusion Criteria:

          -  Patients who are currently being treated with Vidaza®.

          -  Patients who are concurrently participating in a clinical trial.

          -  Patients unwilling or unable to complete the baseline and follow-up questionnaires.

          -  Patients who are deemed inappropriate for treatment with Vidaza®.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David L. Grinblatt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NorthShore University HealthSystem Research Institute</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 31, 2013</lastchanged_date>
  <firstreceived_date>May 30, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
